NeuroSense Therapeutics Ltd. (NRSN)
NASDAQ: NRSN · Real-Time Price · USD
1.090
-0.010 (-0.91%)
At close: Feb 21, 2025, 4:00 PM
1.080
-0.010 (-0.92%)
After-hours: Feb 21, 2025, 4:48 PM EST
NeuroSense Therapeutics Stock Forecast
Stock Price Forecast
There is currently no analyst price target forecast available for NeuroSense Therapeutics.
Analyst Consensus: Hold
Analyst Ratings
According to 1 stock analyst, the rating for NeuroSense Therapeutics is "Hold". This means that the analyst believes this stock is likely to perform similarly to the overall market.
Recommendation Trends
Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 |
---|---|---|---|---|
Strong Buy | 1 | 0 | 0 | 0 |
Buy | 0 | 0 | 0 | 0 |
Hold | 0 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 |
Total | 1 | 1 | 1 | 1 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Maxim Group | Maxim Group | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Dec 16, 2024 |
Alliance Global Partners | Alliance Global Partners | Strong Buy Initiates $7.5 | Strong Buy | Initiates | $7.5 | +588.07% | Jul 17, 2023 |
Maxim Group | Maxim Group | Strong Buy Initiates $7 | Strong Buy | Initiates | $7 | +542.20% | Jan 7, 2022 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-0.61
from -0.74
EPS Next Year
-0.52
from -0.61
Revenue Forecast
Revenue | 2024 | 2025 | 2026 |
---|---|---|---|
High | n/a | n/a | n/a |
Avg | n/a | n/a | n/a |
Low | n/a | n/a | n/a |
Revenue Growth
Revenue Growth | 2024 | 2025 | 2026 |
---|---|---|---|
High | - | - | - |
Avg | - | - | - |
Low | - | - | - |
EPS Forecast
EPS | 2024 | 2025 | 2026 |
---|---|---|---|
High | -0.58 | -0.43 | -0.35 |
Avg | -0.61 | -0.52 | -0.45 |
Low | -0.64 | -0.59 | -0.54 |
EPS Growth
EPS Growth | 2024 | 2025 | 2026 |
---|---|---|---|
High | - | - | - |
Avg | - | - | - |
Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.